VectorY Taps Biotech Veteran to Steer Neuro-Therapy Pipeline

AMSTERDAM & BOSTON – February 05, 2026 – In a move signaling a significant acceleration of its clinical and corporate ambitions, VectorY Therapeutics has appointed Dr. Kevin Pojasek, a seasoned biotech architect with a formidable track record of building and scaling innovative life science companies, to its Board of Directors. The appointment places a proven strategist and dealmaker inside a company at the vanguard of developing vectorized antibody therapies for devastating neurodegenerative diseases like ALS and Alzheimer's.

VectorY, which secured a landmark €129 million ($138 million) Series A financing in late 2023, is transitioning from a promising early-stage firm into a clinical-stage entity. The addition of Dr. Pojasek is a clear strategic maneuver to guide the company through this critical growth phase, leveraging his deep expertise in corporate strategy, financing, and business development to navigate the high-stakes landscape of neurodegenerative drug development.

“Kevin’s track record of building and guiding high-impact biotech companies makes him an exceptional addition to our board at VectorY,” said Adam Rosenberg, chair of the board at VectorY. “His strategic insight and deep industry experience will be invaluable as we continue to advance patient care with new and novel approaches to address unmet treatment needs in neurodegenerative disease.”

A Proven Architect for Biotech Growth

Dr. Pojasek is not merely an advisor; he is a hands-on builder of biotech enterprises. His career is distinguished by his ability to identify promising science, secure substantial capital, and forge high-value strategic partnerships. This pattern of success is precisely what a company like VectorY needs as it prepares to move its lead candidates into human trials.

His most notable achievements include co-founding Quartet Medicine while an Entrepreneur-in-Residence at Atlas Venture. As its president and CEO, he not only raised over $23 million in Series A capital but also orchestrated a strategic partnership and option-to-acquire deal with pharmaceutical giant Merck, valued at up to $595 million. This demonstrated an early ability to translate nascent science into significant corporate value.

His tenure as chief strategy and business officer at Immunocore further solidified this reputation. There, he was instrumental in shaping corporate and R&D strategy and was pivotal in securing a $40 million investment from the Bill & Melinda Gates Foundation to advance the company's infectious disease programs. Currently, as president and CEO of Enara Bio, he is leading the charge in developing T-cell engager therapies for solid tumors, having guided the company since 2018.

This extensive history of leadership, which also includes co-founding Catamaran Bio and raising a $42 million Series A, and serving as a Venture Partner at SV Health Investors, provides VectorY with a board member who understands the entire lifecycle of a biotech company—from its foundational science to its ultimate market strategy.

Accelerating a Novel Attack on Neurodegeneration

Dr. Pojasek joins VectorY at a pivotal moment. The company, founded in 2020, has rapidly established itself as a leader in a highly specialized field: vectorized antibodies. This innovative platform combines the target-specific precision of antibody therapies with the durable, one-time delivery mechanism of adeno-associated virus (AAV) gene therapy. The goal is to deliver therapeutic antibodies directly to the central nervous system to arrest or even reverse disease progression.

The company’s pipeline targets some of the most challenging and underserved diseases. Its lead program, VTx-002, is aimed at the TDP-43 protein aggregate implicated in Amyotrophic Lateral Sclerosis (ALS) and is poised for clinical development. This is complemented by a broader portfolio, including VTx-001 for ALS, VTx-003 for Huntington’s disease, VTx-004 for frontotemporal dementia (FTD), and VTx-005, which targets phosphorylated tau in Alzheimer’s disease.

The significant capital from its 2023 Series A, co-led by EQT Life Sciences and Forbion, provides the financial firepower to advance this ambitious pipeline. Now, the focus shifts to execution: navigating complex regulatory pathways, scaling manufacturing, and designing and running effective clinical trials. This is precisely the operational and strategic gauntlet where Dr. Pojasek’s experience becomes most critical.

Broad Expertise for a Specialized Challenge

While Dr. Pojasek’s recent focus has been in oncology with Enara Bio, his appointment highlights a growing trend in biotechnology: leveraging cross-disciplinary leadership to solve complex biological problems. The strategic challenges of developing advanced biologics—whether they are T-cell engagers for cancer or vectorized antibodies for neurodegeneration—share common ground in manufacturing, immunogenicity, delivery, and regulatory science.

Furthermore, his background is not limited to oncology. His earlier career included leadership roles at Satori Pharmaceuticals, where he oversaw development activities for an Alzheimer's disease program, and Solace Pharmaceuticals, where he managed the clinical development of a compound for neuropathic pain. This direct experience in CNS and neuro-related indications provides a specific, relevant foundation for his new role at VectorY.

His diverse background allows him to bring a broader strategic perspective, drawing on lessons learned from different therapeutic areas and technological platforms to inform VectorY’s path forward. This blend of broad strategic acumen and specific CNS experience makes him a uniquely qualified advisor.

Dr. Pojasek himself underscored his alignment with the company’s ambitious vision. “I’m pleased to join the VectorY team at this important stage of the company’s growth,” he stated. “The company’s scientific mission to advance vectorized antibody therapies to create disease-modifying treatments that will potentially reverse neurodegenerative disease and transform patient care strongly resonates with me, and I look forward to supporting this talented team as they advance their platform and drive the next phase of growth and innovation.”

As VectorY prepares to translate its groundbreaking science from the lab to the clinic, the addition of Dr. Pojasek's strategic acumen to its board is a definitive statement of intent. The company is not only developing novel therapies but is also meticulously building the leadership team required to deliver them to patients who have been waiting for a breakthrough.